title: TLK-199 (Telik).
abstract: Telik Inc is developing TLK-199, an intravenous inhibitor of glutathione S-transferase P1-1, for the potential prevention of myelosuppression in blood diseases, namely myelodysplastic syndrome.
authors.affiliation: Sir Mortimer B Davis-Jewish General Hospital, Department of Pharmacology and Therapeutics, McGill University, Montreal, Canada.
authors.forename: David
authors.initials: D
authors.lastname: Hamilton
authors.forename: Gerald
authors.initials: G
authors.lastname: Batist
mesh_terms: D000818:Animals; D001855:Bone Marrow Diseases / Q000188:drug therapy* / Q000473:pathology; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D005978:Glutathione / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D051549:Glutathione S-Transferase pi; D005982:Glutathione Transferase / Q000096:biosynthesis*; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis*
chemical_list: D004791:Enzyme Inhibitors; D007527:Isoenzymes; C096329:gamma-Glu-S-BzCys-PhGly diethyl ester; C496556:GSTP1 protein, human; D051549:Glutathione S-Transferase pi; D005982:Glutathione Transferase; D005978:Glutathione